Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c22f78ac486adee4534dc1c3a59f5de0 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2835 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-421 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6872 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-421 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 |
filingDate |
2018-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_536e1f7bbd778c6e79142fa41ae9ca51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_52f00485499ab0932bf85c8339c7848f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0e12fddcc5ee4b52cd3f06f2af63718 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94a4b668c8497c7054b2a2a9a95f5b7c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6498b98547a3866b2251634874f90f45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f788f40d20b38312645aa2d01fd88fd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc711e061be28866eea1ed514ea6e462 |
publicationDate |
2020-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
AU-2018287319-A1 |
titleOfInvention |
Modulators of alpha-synuclein |
abstract |
The disclosure provides diagnostic methods and methods for treatment of conditions arising from alpha-synucleopathies. An aminopyrazole compound can be used for treatment of such conditions by lowering the amount of alpha-synuclein in cells of a subject. |
priorityDate |
2017-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |